XTL BIOPHARMACEUTICALS LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.9 ILa | 0.00% |
|
-0.99% | +185.71% |
| Apr. 30 | XTL Biopharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Apr. 29 | Top Premarket Gainers | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | - | Sales 2023 | - | Capitalization | 5.28M 1.93B |
|---|---|---|---|---|---|
| Net income 2022 | -1M -366M | Net income 2023 | -1M -366M | EV / Sales 2022 | - |
| Net cash position 2022 | 3.72M 1.36B | Net cash position 2023 | 2.01M 734M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-4.72
x | P/E ratio 2023 |
-2.96
x | Employees | 5 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 93.3% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.01% | ||
| 1 week | -0.99% | ||
| Current month | +6.38% | ||
| 1 month | +6.38% | ||
| 3 months | +185.71% | ||
| 6 months | +170.27% | ||
| Current year | +185.71% |
1 week
9.50
10.20
1 month
8.8010.60
Current year
3.1017.10
1 year
3.0017.10
3 years
3.0017.80
5 years
3.0017.80
10 years
3.0058.90
| Managers | Title | Age | Since |
|---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 14-12-29 |
Itay Weinstein
DFI | Director of Finance/CFO | 52 | 98-12-31 |
Doron Turgeman
CHM | Chairman | 56 | 14-12-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 14-12-29 |
| Director/Board Member | 57 | 20-01-28 | |
| Director/Board Member | 53 | 17-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-22 | 9.9 | 0.00% | 1 031 501 |
| 24-05-21 | 9.9 | +2.06% | 505,365 |
| 24-05-20 | 9.7 | -2.02% | 587,281 |
| 24-05-19 | 9.9 | -1.00% | 295,225 |
| 24-05-16 | 10 | -0.99% | 2,311,161 |
Delayed Quote TEL AVIV STOCK EXCHANGE, May 22, 2024 at 04:25 am EDT
More quotes
XTL Biopharmaceuticals Ltd is an Israel-based biopharmaceutical company engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong the survival of patients for the treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by the kidney. EPO stimulates erythropoiesis, the production of red blood cells, by binding to its receptor on the surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.
| 1st Jan change | Capi. | |
|---|---|---|
| +185.71% | 14.71M | |
| +44.48% | 55.07B | |
| +44.53% | 40.22B | |
| -0.86% | 41.79B | |
| -7.59% | 28.17B | |
| +12.30% | 26.28B | |
| -21.83% | 18.93B | |
| +7.15% | 13.03B | |
| +29.40% | 12.26B | |
| +25.15% | 12.21B |
- Stock Market
- Equities
- XTLB Stock